CTKB · Nasdaq
It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
Cytek Biosciences, Inc (the “Company” or “Cytek”) requires additional time to complete its financial closing procedures as of the end of the reporting period impacting the Company due to a lack of internal accounting resources, resulting in a delay in obtaining and compiling required information. Accordingly, the Company is not able to complete the preparation, review and filing of its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) within the prescribed time period without unreasonable effort or expense. The Company expects to report unremediated material weaknesses in its Form 10-K, consistent with its prior report on Form 10-Q for the fiscal quarter ended September 30, 2023 filed with the Securities and Exchange Commission on November 14, 2023. The Company currently expects to file its Form 10-K on or before March 15, 2024, the prescribed due date pursuant to this Form 12b-25
NT 10-K, filed 2024-03-01 · material weakness
Cytek Biosciences, Inc (the “Company” or “Cytek”) requires additional time to complete its financial closing procedures as of the end of the reporting period impacting the Company due to a lack of internal accounting resources, resulting in a delay in obtaining and compiling required information. Accordingly, the Company is not able to complete the preparation, review and filing of its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) within the prescribed time period without unreasonable effort or expense. The Company expects to report unremediated material weaknesses in its Form 10-K, consistent with its prior report on Form 10-Q for the fiscal quarter ended September 30, 2023 filed with the Securities and Exchange Commission on November 14, 2023. The Company currently expects to file its Form 10-K on or before March 15, 2024, the prescribed due date pursuant to this Form 12b-25
Cytek Biosciences, Inc (the “Company” or “Cytek”) requires additional time to complete its financial closing procedures and ensure appropriate accounting of various intercompany transactions and accruals at the end of the reporting period impacting the Company. Accordingly, the Company is not able to complete the preparation, review and filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense. The Company currently expects to file its Form 10-Q on or before November 14, 2023, the prescribed due date pursuant to this Form 12b-25
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice